1. Home
  2. LSBK vs CUE Comparison

LSBK vs CUE Comparison

Compare LSBK & CUE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • LSBK
  • CUE
  • Stock Information
  • Founded
  • LSBK 1891
  • CUE 2014
  • Country
  • LSBK United States
  • CUE United States
  • Employees
  • LSBK N/A
  • CUE N/A
  • Industry
  • LSBK Savings Institutions
  • CUE Biotechnology: Pharmaceutical Preparations
  • Sector
  • LSBK Finance
  • CUE Health Care
  • Exchange
  • LSBK Nasdaq
  • CUE Nasdaq
  • Market Cap
  • LSBK 91.1M
  • CUE 91.9M
  • IPO Year
  • LSBK 2006
  • CUE 2018
  • Fundamental
  • Price
  • LSBK $15.80
  • CUE $1.49
  • Analyst Decision
  • LSBK
  • CUE Strong Buy
  • Analyst Count
  • LSBK 0
  • CUE 5
  • Target Price
  • LSBK N/A
  • CUE $5.00
  • AVG Volume (30 Days)
  • LSBK 4.1K
  • CUE 254.0K
  • Earning Date
  • LSBK 01-24-2025
  • CUE 03-10-2025
  • Dividend Yield
  • LSBK 4.56%
  • CUE N/A
  • EPS Growth
  • LSBK 7.32
  • CUE N/A
  • EPS
  • LSBK 0.88
  • CUE N/A
  • Revenue
  • LSBK $25,846,000.00
  • CUE $9,532,000.00
  • Revenue This Year
  • LSBK N/A
  • CUE $73.11
  • Revenue Next Year
  • LSBK N/A
  • CUE $11.02
  • P/E Ratio
  • LSBK $17.95
  • CUE N/A
  • Revenue Growth
  • LSBK N/A
  • CUE 149.53
  • 52 Week Low
  • LSBK $10.30
  • CUE $0.45
  • 52 Week High
  • LSBK $16.56
  • CUE $2.37
  • Technical
  • Relative Strength Index (RSI)
  • LSBK 64.39
  • CUE 58.61
  • Support Level
  • LSBK $15.51
  • CUE $1.22
  • Resistance Level
  • LSBK $16.56
  • CUE $1.50
  • Average True Range (ATR)
  • LSBK 0.42
  • CUE 0.12
  • MACD
  • LSBK 0.08
  • CUE 0.00
  • Stochastic Oscillator
  • LSBK 75.95
  • CUE 96.67

About LSBK Lake Shore Bancorp Inc.

Lake Shore Bancorp Inc operates as a savings and loan holdings company. The bank's business consists of attracting retail deposits from the general public in the areas surrounding its branch offices and investing those deposits, together with funds generated from operations, in commercial real estate loans, one-to-four family residential mortgage loans, home equity lines of credit and, to a lesser extent, commercial business loans, consumer loans, and investment securities. Its revenues are principally derived from interest earned on loans and investment securities.

About CUE Cue Biopharma Inc.

Cue Biopharma Inc is a clinical-stage biopharmaceutical company. It is developing a novel and proprietary class of biologics drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. Its objective is to provide patients suffering from cancer and autoimmune disease with dramatically improved therapeutic outcomes through the platform of biologic drug product candidates. The other products under pipeline are CUE-101 as a Monotherapy, CUE-101 + Pembrolizumab, CUE-102, CUE-103 and others.

Share on Social Networks: